US4837226A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Polycyclic amine derivatives useful as cerebrovascular agents
Assignee: Warner Lambert Co LLC
•
Filing: 1988-04-27
•
Granted: 1989-06-06
•
Expires: 2008-04-27
Abstract
Abstract A method for the treatment of cerebrovascular disorders by administering a fluorenamine, dibenzofuranamine, or dibenzothiophenamine derivative.
Inventors
- 👤 Linda L. Coughenour
- 👤 Graham Johnson
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-11-09 02:45
CPC Classifications
C; C07; C07D; C07D307/00; C07D307/77; C07D307/91; A; A61; A61K; A61K31/00; A61K31/13; A61K31/135; A61K31/33; A61K31/335; A61K31/34; A61K31/357; A61K31/36; A61K31/38; A61P; A61P25/00; A61P25/04; A61P25/28; A61P9/00; C07C; C07C211/00; C07C211/33; C07C211/39; C07C211/41; C07C211/42; C07C217/00; C07C217/02; C07C217/04; C07C217/06; C07C217/08; C07D333/00; C07D333/50; C07D333/76; C07C2603/00; C07C2603/02; C07C2603/04; C07C2603/06; C07C2603/10; C07C2603/12; C07C2603/18
Claims Analysis
Total Claims: 15
Claim 1
Independent Claim
97 words
A method for treating cerebrovascular disorders which comprises administering to a patient a therapeutically effective amount of a compound of the formula ##STR4## or a pharmaceutically acceptable acid addition salt thereof wherein: Z is methylene, oxygen, or sulfur; R 1 is hydrogen, lower alkyl, or lower alkoxyalkyl; R 2 is hydrogen or lower alkyl; R 3 and R 4 are each independently hydrogen or when taken together are methylenedioxy; A is --CH 2 CH 2 --, --CH═CH-- or when Z is methylene A is --CMe═CMe--, --CHMeCHMe--, --CHMeCH 2 --, --CMe═CH--, --CH 2 CH 2 --, or --CH═CH--.
Claim 2
Independent Claim
97 words
A method for treating cerebrovascular disorders which comprises administering to a patient a therapeutically effective amount of a compound of the formula ##STR4## or a pharmaceutically acceptable acid addition salt thereof wherein: Z is methylene, oxygen, or sulfur; R 1 is hydrogen, lower alkyl, or lower alkoxyalkyl; R 2 is hydrogen or lower alkyl; R 3 and R 4 are each independently hydrogen or when taken together are methylenedioxy; A is --CH 2 CH 2 --, --CH═CH-- or when Z is methylene A is --CMe═CMe--, --CHMeCHMe--, --CHMeCH 2 --, --CMe═CH--, --CH 2 CH 2 --, or --CH═CH--.
Claim 3
Dependent Claim
61 words
A method for treating cerebrovascular disorders according to claim 1 wherein in a compound of formula I: Z is methylene or sulfur, R 1 is hydrogen, methyl, ethyl, propyl, or (CH 2 ) 3 OMe, R 2 is hydrogen or methyl, and A is --CH 2 CH 2 --, --CH═CH-- or when Z is methylene A is also --CH(Me)CH 2 --.
Claim 4
Dependent Claim
34 words
A method for treating cerebrovascular disorders according to claim 1 wherein the compound is selected from the group consisting of: 1,4,9,9a-tetrahydro-4aH-fluoren-4a-amine, 1,4,9,9a-tetrahydro-N-methyl-4aH-fluoren-4a-amine, 1,4,9,9a-tetrahydro-N,N-dimethyl-4aH-fluoren-4a-amine, N-ethyl-1,4,9,9a-tetrahydro-4aH-fluoren-4a-amine, 1,4,9,9a-tetrahydro-N-propyl-4aH-fluoren-4a-amine, N-butyl-1,4,9,9a-tetrahydro-4aH-fluoren-4a-amine, 1,4,9,9a-tetrahydro-N-pentyl-4aH-fluoren-4a-amine, 1,4,9,9a-tetrahydro-3-methyl-4aH-fluoren-4a-amine, 1,4,9,9a-tetrahydro-3-methyl-N-methyl-4aH-fluoren-4a-amine, 1,4,9,9a-tetrahydro-3-methyl-N-ethyl-4aH-fluoren-4a-amine, N-ethyl-1,2,3,4,9,9a-hexahydro-4aH-fluoren-4a-amine, 1,2,3,4,9,9a-hexahydro-N,N-dimethyl-4aH-fluoren-4a-amine, N-ethyl-1,2,3,4,9,9a-hexahydro-4aH-fluoren-4a-amine, 1,2,3,4,9,9a-hexahydro-N-propyl-4aH-fluoren-4a-amine,
Claim 5
Dependent Claim
12 words
2,3,4,9,9a-hexahydro-2,3-dimethyl-N-methyl-4aH-fluoren-4a-amine, 6,7,8,9-tetrahydro-9a(5aH)-dibenzofuranamine, 6,7,8,9-tetrahydro-N-methyl-9a(5aH)-dibenzofurananamine, N-ethyl-6,7,8,9-tetrahydro-N-methyl-9a(5aH)-dibenzofuranamine, 6,7,8,9-tetrahydro-N-propyl-9a(5aH)-dibenzofuranamine, 6,7,8,9-tetrahydro-N-(methoxypropyl)-9a(5aH)-dibenzofuranamine, N-ethyl-6,7,8,9-tetrahydro-N-methyl-9a(5aH)-dibenzothiophenamine, 6,9-dihydro-N-methyl-9a-(5aH)-dibenzothiophenamine, 6,9-dihydro-N,N-dimethyl-9a-(5aH)-dibenzothiophenamine, 2,5,6,7,8,9-hexahydro-N-methyl-4bH-fluoreno[2,3-d]-1,3-dioxole-4b-amine, and N-ethyl-2,5,6,7,8,9-hexahydro-4bH-fluoreno[2,3-d]-1,3-dioxole-4b-amine.
Claim 6
Dependent Claim
12 words
2,3,4,9,9a-hexahydro-2,3-dimethyl-N-methyl-4aH-fluoren-4a-amine, 6,7,8,9-tetrahydro-9a(5aH)-dibenzofuranamine, 6,7,8,9-tetrahydro-N-methyl-9a(5aH)-dibenzofurananamine, N-ethyl-6,7,8,9-tetrahydro-N-methyl-9a(5aH)-dibenzofuranamine, 6,7,8,9-tetrahydro-N-propyl-9a(5aH)-dibenzofuranamine, 6,7,8,9-tetrahydro-N-(methoxypropyl)-9a(5aH)-dibenzofuranamine, N-ethyl-6,7,8,9-tetrahydro-N-methyl-9a(5aH)-dibenzothiophenamine, 6,9-dihydro-N-methyl-9a-(5aH)-dibenzothiophenamine, 6,9-dihydro-N,N-dimethyl-9a-(5aH)-dibenzothiophenamine, 2,5,6,7,8,9-hexahydro-N-methyl-4bH-fluoreno[2,3-d]-1,3-dioxole-4b-amine, and N-ethyl-2,5,6,7,8,9-hexahydro-4bH-fluoreno[2,3-d]-1,3-dioxole-4b-amine.
Claim 7
Dependent Claim
11 words
A method according to claim 1 wherein the compound is: N-ethyl-6,7,8,9-tetrahydro-9a(5aH)-dibenzofuranamine.
Claim 8
Dependent Claim
11 words
A method according to claim 1 wherein the compound is: 6,7,8,9-tetrahydro-N-methyl-9a(5aH)-dibenzothiophenamine.
Claim 9
Dependent Claim
11 words
A method according to claim 1 wherein the compound is: 1,2,3,4,9,9a-hexahydro-4aH-fluoren-4a-amine.
Claim 10
Dependent Claim
11 words
A method according to claim 1 wherein the compound is: 1,2,3,4,9,9a-hexahydro-N-(3-methoxypropyl)-4aH-fluoren-4a-amine.
Claim 11
Dependent Claim
11 words
A method according to claim 1 wherein the compound is: 1,2,3,4,9,9a-hexahydro-N-methyl-4aH-fluoren-4a-amine.
Claim 12
Dependent Claim
11 words
A method according to claim 1 wherein the compound is: 1,2,3,4,9,9a-hexahydro-3-methyl-N-methyl-4aH-fluoren-4a-amine.
Claim 13
Dependent Claim
26 words
A method according to claim 1 wherein 0.01 to 50 mg/kg by weight of a compound or pharmaceuticaly acceptable salt thereof is administered to a patient.
Claim 14
Independent Claim
86 words
A method of using as an analgesic a compound of formula ##STR5## or a pharmaceutically acceptable acid addition salt thereof wherein: Z is methylene, oxygen, or sulfur; R 1 is hydrogen, lower alkyl, or lower alkoxyalkyl; R 2 is hydrogen or lower alkyl; R 3 and R 4 are each independently hydrogen or when taken together are methylenedioxy; A is --CH 2 CH 2 --, --CH═CH-- or when Z is methylene A is --CMe═CMe--, --CHMeCHMe--, --CHMeCH 2 --, --CMe═CH--, --CH 2 CH 2 --, or --CH═CH--.
Claim 15
Independent Claim
86 words
A method of using as an analgesic a compound of formula ##STR5## or a pharmaceutically acceptable acid addition salt thereof wherein: Z is methylene, oxygen, or sulfur; R 1 is hydrogen, lower alkyl, or lower alkoxyalkyl; R 2 is hydrogen or lower alkyl; R 3 and R 4 are each independently hydrogen or when taken together are methylenedioxy; A is --CH 2 CH 2 --, --CH═CH-- or when Z is methylene A is --CMe═CMe--, --CHMeCHMe--, --CHMeCH 2 --, --CMe═CH--, --CH 2 CH 2 --, or --CH═CH--.
References Cited (Backward Citations)
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1992-06-05 | 1992-12-05 | 1993-06-06 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1996-06-05 | 1996-12-05 | 1997-06-06 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 2000-06-05 | 2000-12-05 | 2001-06-06 | $7700.00 | Window Closed / Lapsed |